Astria Stockholders Vote to Approve Acquisition by BioCryst

Reviewing Swedish Orphan Biovitrum (OTCMKTS:BIOVF) & Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving Average – Here’s What Happened

Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS)

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders

BioCryst to buy Astria Therapeutics in $700 million deal

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema

Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial

Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology

All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy

Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade

Astria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 Transcript

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress